Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8 + T cell dysfunction and maintain memory phenotype
Abstract
Synergistic CD8 + T cell activation by antibodies to PD-1 and GITR in cancer immunotherapy depends on the CD226 costimulatory pathway.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A series of preclinical studies showed that co-stimulatory molecule agonists improved α-PD-1/PD-L1 efficacy.
“A series of preclinical studies showed that co-stimulatory molecule agonists improved α-PD-1/PD-L1 efficacy [170–176].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [175]
The citation lists haven’t been fetched yet
References 51 · Cited by 167
- Authors
- Wang, B., Zhang, W., Jankovic, V., Golubov, J., Poon, P., Oswald, E. M., Gurer, C., Wei, J., Ramos, I., Wu, Q., Waite, J., Ni, M., Adler, C., Wei, Y., Macdonald, L., Rowlands, T., Brydges, S., Siao, J., Poueymirou, W., MacDonald, D., Yancopoulos, G. D., Sleeman, M. A., Murphy, A. J., & Skokos, D.
- Affiliations
- Regeneron (United States) (US)
- Regeneron Pharmaceuticals,Tarrytown, New York, NY 10591, USA.
- Corresponding author
- Wang, Bei
- Zhang, Wen
- Skokos, Dimitris
- ORCID
- Venue
- Science Immunology
- Published
- 2018-11-30
- Volume
- 3
- Issue
- 29
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W2899058237
- Cited by
- 167
- References
- 51
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 19 · 2023: 25 · 2022: 19 · 2021: 32 · 2020: 34 · 2019: 15 · 2018: 2
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, GITR, cancer immunotherapy, CD8+ T cell dysfunction, memory T cells, CD226, TIGIT, antitumor immunity
- MeSH terms
- T Lineage-Specific Activation Antigen 1, Animals, Antigens, Differentiation, T-Lymphocyte, Female, Immunologic Memory, Immunotherapy, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms, Phenotype, Mice, Knockout, CD8-Positive T-Lymphocytes, Mice, Glucocorticoid-Induced TNFR-Related Protein, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
